Benzonatate (Tessalon) is Safe for Patients with Hypertension and CHF
Benzonatate can be safely used in patients with hypertension and congestive heart failure, as it has no direct cardiovascular effects and does not interact with standard heart failure or antihypertensive medications.
Cardiovascular Safety Profile
The FDA drug label for benzonatate 1 contains no contraindications or warnings specific to hypertension or heart failure. The precautions focus entirely on:
- CNS effects related to para-aminobenzoic acid sensitivity
- Risk of local anesthesia if capsules are chewed
- Overdose risks (particularly in children and adults)
Notably absent from the precautions are any warnings about:
- Cardiovascular disease
- Blood pressure effects
- Interactions with diuretics, ACE inhibitors, ARBs, beta-blockers, or other cardiac medications
- Fluid retention or worsening heart failure
Mechanism and Lack of Systemic Effects
Benzonatate is a peripherally acting antitussive that works by anesthetizing stretch receptors in the respiratory passages 1. It does not:
- Affect blood pressure
- Alter cardiac contractility
- Cause fluid retention
- Interact with the renin-angiotensin-aldosterone system
- Interfere with diuretic efficacy
Critical Safety Considerations (Unrelated to HTN/CHF)
While safe for cardiovascular patients, benzonatate carries serious overdose risks that warrant careful prescribing:
- Rapid toxicity: Signs of overdose can appear within 15-20 minutes, with death reported within one hour 1
- Cardiac arrest risk: Multiple case reports document cardiac arrest from overdose 2, 3, but these are toxicity-related, not disease-interaction issues
- Strict dosing limits: Never exceed 200 mg per dose or 600 mg daily 1
Patient Education Requirements
- Swallow capsules whole—never chew, crush, or dissolve
- Keep out of reach of children (accidental ingestion is fatal)
- If numbness of mouth/throat occurs, avoid eating/drinking until resolved
Clinical Bottom Line
There is no evidence-based reason to avoid benzonatate in patients with well-managed or poorly-controlled hypertension and heart failure. The drug does not interfere with guideline-directed medical therapy for HF 4 or standard antihypertensive regimens 5. The documented safety concerns relate exclusively to overdose and improper administration, not to cardiovascular comorbidities.